El interés en corto de Tilray Brands da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Tilray Brands. Los datos de interés en corto se actualizan cada dos semanas.

Tilray Brands (NASDAQ:TLRY) Bolsa, Informe de interés en corto

Tilray Brands

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

Tilray Brands Inc

TILRAY BRANDS ORD

Earnings

News

TLRY

Tilray Brands Q1 2025 Adj. EPS $(0.01) Beats $(0.04) Estimate, Sales $200.044M Miss $219.295M Estimate

The imminent release of the<a href="https://www.benzinga.com/markets/24/10/41251483/september-inflation-preview-consumer-price-data-holds-the-key-to-feds-next-interest-rate-move"> September consumer price inflation report </a>is keeping sentiment guarded as the index futures trade modestly lower early Thursday. Traders may have to navigate past the September consumer price inflation report and the weekly jobless claims data, both of which have implications for rates. The inflation data is widely expected to confirm the sustained downtrend, while jobless claims may have perked up in the recent week. 
China announced stimulus to support the domestic stock market, which sent stocks in the mainland and Hong Kong higher. Crude oil and gold are all weaker but the bond yield has ticked. Traders may stay focused on the after-effects of Hurricane Milton and the simmering tensions in the Middle East.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.15%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.12%</td>
</tr>
<tr>
<td>Dow</td>
<td>-0.09%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.24%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Thursday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) edged down 0.13% to $576.41 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) moved down 0.16% to $492.35, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
Strength in IT, financial, industrial and healthcare stocks pushed the Dow Jones Industrial Average and the S&amp;P 500 Index to fresh records on Wednesday. The S&amp;P 500 Index also clocked a new intraday high. While the tech-heavy Nasdaq Composite also rose, it ended at its highest level since July 16.
Stocks largely ignored the Hurricane Milton threat, which made its landfall in Florida, and digested comments from Fed officials and also information gleaned out of the Fed minutes. 
Among S&amp;P 500 sector classes, only communication services and utility stocks experienced some weakness.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+0.60%</td>
<td>18,291.62</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+0.71%</td>
<td>5,792.04</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+1.03%</td>
<td>42,512.00</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>+0.26%</td>
<td>2,200.59</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
A Morgan Stanley strategist on Wednesday weighed on the impact of the potential trade policies of the two presidential candidates. &#8220;Trade policy is among the top policy areas that may be most sensitive to the presidential election result,&#8221; said Monica Guerra, Head of Policy, Morgan Stanley Wealth Management. 
The impact of tariffs on the economy could be wide-ranging, pressuring consumers and affecting growth, inflation and stock market performance, she said. Vice President Kamala Harris&#8217; trade policy appears to be a continuation of President Joe Biden's, but is still opaque, creating some uncertainty for investors, while Republican candidate Donald Trump&#8217;s proposals included increasing tariffs on China as well as a universal tariff, which could pressure productivity, growth and add inflationary pressure, she said.
The strategist recommended investors mitigate the impact of tariffs by considering defensive sectors such as consumer staples, healthcare and utilities, as well as select retailers with less exposure to offshore production.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data:
<ul>
<li>The Labor Department is scheduled to release its customary weekly jobless claims report at 8:30 a.m. EDT. Economists, on average, expect the number of individuals claiming unemployment benefits to come in at 230,000 for the week ended Oct. 5, up from 225,000 in the previous week.</li>
<li>The September CPI report, due at 8:30 a.m. EDT, is expected to show a 0.1% month-over-month increase in the headline number, a tick down from the 0.2% growth in August. The annual rate of CPI is expected to slow from 2.5% to 2.3%. The monthly and annual core CPI rates for September are expected at 0.2% and 3.2%, respectively, compared to August&#8217;s 0.3% and 3.2%.</li>
<li>Among the Fed speakers due to speak are:
<ul>
<li>Federal Reserve Governor Lisa Cook: 9:15 a.m. EDT</li>
<li>Chicago Fed President Austan Goolsbee (TV interview): 10 a.m. EDT</li>
<li>Richmond Fed President Tom Barkin: 10:30 a.m. EDT</li>
<li>New York Fed President John Williams: 11 a.m. EDT</li>
</ul>
</li>
<li>The Treasury will auction four- and eight-week bills at 11:30 a.m. EDT and 30-year bonds at 1 p.m. EDT.</li>
</ul>
Stocks In Focus:
<ul>
<li>GXO Logistics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>), a spin-off unit of XPO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>), rose about 6% <a href="https://benzinga.grsm.io/register174">in premarket trading </a>after Bloomberg said the company is rumored to be exploring a potential sale.</li>
<li>10x Genomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) slumped over 21% following the company&#8217;s preannouncement.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose over 1% <a href="https://www.benzinga.com/news/24/10/41266991/teslas-robotaxi-to-take-flight-with-doors-that-open-like-butterfly-wings-report">ahead of its Robotaxi event.</a></li>
<li>Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) and Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) are among the notable companies due to <a href="https://www.benzinga.com/calendars/earnings">report their quarterly results ahead of the market open.</a></li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures climbed sharply ahead of the inflation data and gold futures were modestly higher. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) pulled back nearly 2% over the past 24 hours and has slipped under $61K. The 10-year Treasury note yield rose 1.5 points to 4.082%.
Most major Asian markets ended higher for the day, as domestic traders drew inspiration from the positive close on Wall Street overnight. The Chinese and Hong Kong markets led the gains in the region after the <a href="https://www.benzinga.com/markets/asia/24/10/41265266/alibaba-jd-com-xpeng-soar-in-hong-kong-as-pbocs-fresh-stimulus-to-boost-stock-market-sends-chinese-m">People&#8217;s Bank of China announced new stimulus</a> to support the stock market. 
On the other hand, European stocks retreated in early trading 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41266843/marjorie-taylor-greene-boosts-stock-portfolio-with-ai-exposure-buys-jpmorgan-and-this-hot-magnif">Marjorie Taylor Greene Boosts Stock Portfolio With AI Exposure, Buys JPMorgan And This Hot Magnificent 7 Stock: Here&#8217;re Congresswoman&#8217;s Latest Trades</a></li>
</ul>
Photo via Shutterstock

Equities

Futures

Economics

Federal Reserve

Markets

Trading Ideas

$BTC

TSLA

Nasdaq, S&P 500 Futures Slip As September CPI Data Looms, Tesla On Radar Ahead Of Robotaxi Event: Strategist Offers Stock Tips Aligned With Presidential Candidates' Trade Policies

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Wednesday.
U.S. stocks settled higher on Wednesday, with the Dow Jones and S&amp;P 500 settling at record levels during the session. Tech stocks were among the top gainers, with shares of Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) adding more than 1% on Wednesday.
Investors digested the minutes from the September Federal Open Market Committee (FOMC) meeting, which revealed extensive debate over whether to cut rates by 25 or 50 basis points. Ultimately, the committee opted for the larger 50-basis-point cut, but the discussion underscored the ongoing uncertainty about the Federal Reserve&#8217;s next moves.
On the economic data front, U.S. wholesale inventories increased by 0.1% month-over-month to $904.8 billion in August, compared to the preliminary estimate of a 0.2% gain and versus a revised 0.2% rise in the previous month.
Data on Consumer Price Index inflation will be released on Thursday.
Most sectors on the S&amp;P 500 closed on a positive note, with healthcare, information technology, and industrials stocks recording the biggest gains on Wednesday. However, utilities and communication services stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 432 points to 42,512.00 on Wednesday. The S&amp;P 500 rose 0.71% to 5,792.04, while the Nasdaq Composite climbed 0.60% at 18,291.62 during Wednesday's session.
Investors are awaiting earnings results from Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) and Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 72.2, the index remained in the &#8220;Greed&#8221; zone on Wednesday, versus a prior reading of 70.6.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41262752/top-3-industrials-stocks-which-could-blast-off-this-quarter">Top 3 Industrials Stocks Which Could Blast Off This Quarter</a></li>
</ul>

Pre-Market Outlook

AAPL

AMZN

S&P Settles At Record High As Apple, Amazon Shares Surge: Investor Optimism Improves Ahead Of Inflation Data

With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) to report quarterly earnings at $1.52 per share on revenue of $14.67 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Delta Air shares gained 0.1% to $51.00 in after-hours trading.</li>
<li>AZZ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) reported better-than-expected earnings for its second quarter, while sales missed estimates. The company said it sees FY24 adjusted earnings of $4.70 to $5.10 per share on sales of $1.525 billion to $1.625 billion. AZZ shares fell 1.3% to $80.50 in the after-hours trading session.</li>
<li>Analysts are expecting Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) to post quarterly earnings at $3.65 per share on revenue of $1.1 billion. The company will release earnings before the markets open. Domino&#8217;s shares gained 0.7% to $416.24 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>10x Genomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) reported preliminary revenue of $151.7 million for the third quarter, down 1% year over year. 10x Genomics shares dipped 26% to $15.40 in the after-hours trading session.</li>
<li>Analysts expect Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) to post a quarterly loss at 4 cents per share on revenue of $219.3 million before the opening bell. Tilray Brands shares fell 1.2% to close at $1.63 on Wednesday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41262752/top-3-industrials-stocks-which-could-blast-off-this-quarter">Top 3 Industrials Stocks Which Could Blast Off This Quarter</a></li>
</ul>
Photo courtesy: Delta Air Lines

Delta Air Lines, Domino's Pizza And 3 Stocks To Watch Heading Into Thursday

Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) is preparing to release its quarterly earnings on Thursday, 2024-10-10. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Tilray Brands to report an earnings per share (EPS) of $-0.04.
Investors in Tilray Brands are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.06, which was followed by a 9.84% increase in the share price the next day.
Here's a look at Tilray Brands's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.02</td>
<td>-0.05</td>
<td>-0.06</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0</td>
<td>0</td>
<td>-0.1</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>-2.0%</td>
<td>-5.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1728482452_0_0.png" alt="eps graph" />
<h3>Tilray Brands Share Price Analysis</h3>
Shares of Tilray Brands were trading at $1.65 as of October 08. Over the last 52-week period, shares are down 17.09%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/TLRY/earnings">To track all earnings releases for Tilray Brands visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Tilray Brands

Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) is set to give its latest quarterly earnings report on Thursday, 2024-10-10. Here's what investors need to know before the announcement.
Analysts estimate that Tilray Brands will report an earnings per share (EPS) of $-0.04. 
Investors in Tilray Brands are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.06, which was followed by a 9.84% increase in the share price the next day.
Here's a look at Tilray Brands's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.02</td>
<td>-0.05</td>
<td>-0.06</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0</td>
<td>0</td>
<td>-0.1</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>-2.0%</td>
<td>-5.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1728482445_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Tilray Brands were trading at $1.65 as of October 08. Over the last 52-week period, shares are down 17.01%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/TLRY/earnings">To track all earnings releases for Tilray Brands visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Tilray Brands's Earnings

Canopy Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) has built a strategic portfolio of U.S. cannabis assets through its Canopy USA (CUSA) entity. This portfolio includes prominent brands like Wana, a leading edibles producer, Jetty, known for its solventless vapes and multi-state operator Acreage Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ACRHF#OTC">ACRHF</a>).
According to senior analyst <a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic </a>from Zuanic &amp; Associates, these assets position Canopy USA for growth, with potential further upside from federal regulatory changes.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Focus On Brand Expansion</h3>
Zuanic says Canopy USA&#8217;s strategy is to scale its brands, such as Wana and Jetty, by expanding product lines and entering new markets. &#8220;The goal is to build a portfolio of differentiated brands with unique attributes in key segments,&#8221; Zuanic states, suggesting the company will focus on expanding in existing states rather than new ones, with <a href="https://www.benzinga.com/topic/florida-cannabis">Florida being a potential exception</a>.
<h3 class="wp-block-heading">Valuation And Asset Composition</h3>
Zuanic values Canopy USA&#8217;s assets at approximately $617 million. Acreage, the largest asset, is projected to be worth over $411 million, while Wana and Jetty are valued at $125 million combined. Canopy USA also holds a minority stake in TerrAscend (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTC">TSNDF</a>), valued at $81 million.
For context, Canopy Growth's overall enterprise value (EV) is CAD 987 million ($724 million), with Canopy USA accounting for a significant portion. Excluding Canopy USA, Canopy Growth is valued at just CAD 16 million ($11.7 million), significantly lower than competitors Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) (3.5x sales) and Aurora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) (1.9x sales).
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41132320/slipping-weed-sales-in-floridas-market-is-this-100m-bet-really-worth-the-hype">Slipping Weed Sales In Florida&#8217;s Market: Is This $100M Bet Really Worth The Hype?</a>
<h3 class="wp-block-heading">Asset-Light, Brand-First Strategy</h3>
One key takeaway is Canopy USA's &#8220;asset-light&#8221; approach. Zuanic explains that Canopy USA will focus on brand expansion rather than investing heavily in cultivation. &#8220;The Canopy USA structure allows the company to scale brands without building large grow facilities, leveraging partnerships and reciprocity deals.&#8221; 
Retail ownership remains critical, especially in markets with limited licenses. Acreage's retail footprint ensures brand visibility in key dispensaries.
<h3 class="wp-block-heading">Canopy USA's Key Assets</h3>
Wana, a top edibles brand, generated approximately $150 million in retail sales across 19 states in 2023. Jetty, known for its solventless vape technology, commands a price premium in <a href="https://www.benzinga.com/topic/california-cannabis">California</a> and is expanding into New York and New Jersey. Acreage, a multi-state operator, reported $39 million in 2Q24 sales with 5% EBITDA margins.
<h3 class="wp-block-heading">Financial Metrics And Growth Outlook</h3>
Acreage's second-quarter 2024 sales were $39 million, down 33% year-over-year, but gross margins improved to 43.4%. The focus, according to Zuanic, will be on growth in <a href="https://www.benzinga.com/topic/ohio-cannabis">Ohio</a> and Pennsylvania, where adult-use legalization could boost revenues.
Although Wana has faced market share challenges in<a href="https://www.benzinga.com/topic/colorado-cannabis"> Colorado</a>, where its share dropped from 30% to below 20%, Zuanic remains optimistic about its future growth. Jetty holds 3.3% of the California vape market and continues to expand in other states.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41217615/rubicon-organics-83-of-workforce-from-diverse-groups-women-earn-33-more-than-men-cuts-carbon-foo">Rubicon Organics: 83% Of Workforce From Diverse Groups, Women Earn 33% More Than Men, Cuts Carbon Footprint By 48% YoY</a>
<h3 class="wp-block-heading">Comparison With Canadian LPs</h3>
Canopy Growth&#8217;s U.S. strategy via Canopy USA sets it apart from <a href="https://www.benzinga.com/topic/canada-cannabis">Canadian peers</a> like Tilray and Aurora by focusing on brand scalability rather than vertical integration. &#8220;Most Canadian LPs are slow to enter the U.S. market or focus on capital-intensive strategies,&#8221; Zuanic explains, adding that Canopy Growth's asset-light model offers long-term sustainability.
Canopy's financial structure, with an EV of CAD 987 million, is partly distorted by the value of its U.S. assets, which do not yet reflect full market potential.
<h3 class="wp-block-heading">Future Federal Legalization Impact</h3>
Zuanic emphasizes that federal regulatory changes could significantly boost the value of Canopy USA's assets. While Canopy Growth holds non-voting shares in Canopy USA, the structure provides flexibility to consolidate its U.S. assets if cannabis is federally legalized.
For more insights into Canopy USA's valuation methodology, Acreage Holdings' market footprint, detailed brand performance and potential federal impacts, <a href="https://zuanicgroup.com/">Zuanic's full report offers a comprehensive analysis</a>.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41213325/two-cannabis-power-houses-team-up-tilray-brings-cbd-gummies-from-us-medical-marijuana-pioneer-to">Two Cannabis Power Houses Team Up: Tilray Brings CBD Gummies From US Medical Marijuana Pioneer To Canada</a>

Analyst Color

Cannabis

Retail Sales

Legal

Analyst Ratings

ACRHF

TSNDF

Why Canopy's 'Brand-First' Strategy Could Set It Apart From Tilray And Aurora – Here's What Investors Should Watch

Cannabis giant Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>) announced the launch on Monday of new Charlotte&#8217;s Web (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CWEB#TSX">CWEB</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTCQX">CWBHF</a>) CBD gummies in Canada.
The gummies hit shelves in select cannabis retailers across Ontario and will be available in certain provinces and retailers this October and November. Utilizing the Tilray Medical website, the products will be available online as well.
Coming in a 30-pack bottle, the gummies feature two distinct flavors, Berry &amp; Fruit and Turmeric &amp; Ginger, with each product containing 25mg of premium CBD. Gummies feature full-spectrum CBD hemp extract blended with functional herbs and botanical supplements.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07105704/ccc-oct-24-banner__1_-13.gif" alt="" class="wp-image-583691" /></a></figure>
Charlotte's Web Rest Gummies in Berry &amp; Fruit is formulated to support your wind-down routines "post-workout, pre-bedtime, or anywhere between for the ultimate way to rest or reset after a long day," the company said.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
Charlotte's Web Life Gummies in Turmeric &amp; Ginger are formulated to support "an active lifestyle from day to night, helping you conquer your life's busiest days."
The gummies are crafted in the northern Okanagan Valley of British Columbia leveraging Charlotte's Web's proprietary hemp genetics.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40525826/exclusive-new-wana-brands-marketplace-brings-together-martha-stewart-cbd-charlottes-web-cann-pro">EXCLUSIVE: New Wana Brands Marketplace Brings Together Martha Stewart CBD, Charlotte&#8217;s Web, Cann Products</a>
Meanwhile, the billion-dollar Canadian cannabis operator will release its first quarter financial results this Thursday, Oct. 10, before financial markets open, followed by a live conference call to discuss the results at 8:30 am ET the same day.
In July, Tilray reported fiscal fourth-quarter revenue of $229.882 million, up approximately 25% year-over-year. Cannabis net revenue increased&nbsp;12%&nbsp;to&nbsp;$71.9 million in the quarter, while beverage-alcohol net revenue jumped&nbsp;137%&nbsp;to&nbsp;$76.7 million for the period.
Irwin Simon, chairman and CEO of Tilray Brands <a href="https://www.benzinga.com/markets/cannabis/24/07/40023244/tilray-q4-earnings-revenue-eps-beat-as-cannabis-beverages-wellness-converge-on-a-global-scale-dr">said at the time</a> that the company is &#8220;leading the convergence of cannabis, beverages, and wellness on a global scale.&#8221;
<h3 class="wp-block-heading">TLRY Price Action</h3>
Tilray's shares traded 1.4793% lower at $1.665 per share at the time of writing on Monday morning.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/40076821/tilray-ceo-on-future-of-cannabis-and-federal-rescheduling-we-did-not-sit-back-and-wait">Tilray CEO On Future Of Cannabis And Federal Rescheduling: ‘We Did Not Sit Back And Wait'</a>TLRY Price Action</li>
</ul>

CWBHF

CWEB

TSX:CWEB

TSX:TLRY

Two Cannabis Power Houses Team Up: Tilray Brings CBD Gummies From US Medical Marijuana Pioneer To Canada

Tilray Brands, Inc. ("Tilray") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>), a global lifestyle and consumer packaged goods company, announced the launch of new Charlotte's Web (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CWEB#TSX">CWEB</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTCQX">CWBHF</a>) CBD gummies in Canada. Designed specifically for daily CBD consumers, Charlotte's Web CBD Rest Gummies and CBD Life Gummies offer an easy, delicious, and convenient way to incorporate CBD into your wellness routine. &nbsp;
The new gummies are available in a 30-pack bottle with two distinct flavors: Berry &amp; Fruit and Turmeric &amp; Ginger. Each gummy contains 25mg of premium CBD, ensuring a consistent and enjoyable experience.
Crafted in the pristine northern Okanagan Valley of British Columbia, these gummies leverage Charlotte's Web's proprietary hemp genetics. They feature full-spectrum CBD hemp extract, meticulously blended with functional herbs and botanical supplements to provide synergistic support for targeted wellness benefits.

Tilray Introduces New Charlotte's Web CBD Gummies, Bringing Full-Spectrum Hemp to Canadian Consumers

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CWWBF">Plant Based Investment</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWWBF#OTC">CWWBF</a>) shares closed up 9900.00% at $0.0001</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 38.10% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 12.40% at $2.38</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 10.71% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 9.30% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed up 8.73% at $13.20</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 7.11% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 3.84% at $0.01</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/AUSAF">Australis Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUSAF#OTC">AUSAF</a>) shares closed down 99.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 16.41% at $0.18</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 10.40% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 8.30% at $4.41</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed down 7.96% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 6.68% at $19.23</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 5.80% at $1.33</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 4.28% at $0.45</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.98% at $1.68</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 3.76% at $2.05</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed down 3.70% at $2.57</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 3.57% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 3.39% at $1.99</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AUSAF

BBRRF

CBDY

CLSH

CNPOF

CRBP

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CANNIBIS GROWTH OPTY CORP by Cannabis Growth Opportunity Corp.

CWWBF

CXXIF

ELLXF

FFNTF

GRWG

SNDL

TGIFF

UGRO

XXII

YCBD

Cannabis Stock Gainers And Losers From October 1, 2024

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) will release its financial results on Oct. 10, 2024 before financial markets open and host a live conference call to discuss the results at 8:30 am ET the same day.
In July, Tilray reported fiscal fourth-quarter revenue of $229.882 million, up approximately 25% year-over-year. Cannabis net revenue increased&nbsp;12%&nbsp;to&nbsp;$71.9 million in the quarter, while beverage-alcohol net revenue jumped&nbsp;137%&nbsp;to&nbsp;$76.7 million for the period.
Irwin Simon, chairman and CEO of Tilray Brands <a href="https://www.benzinga.com/markets/cannabis/24/07/40023244/tilray-q4-earnings-revenue-eps-beat-as-cannabis-beverages-wellness-converge-on-a-global-scale-dr">said at the time</a> that the company is "leading the convergence of cannabis, beverages, and wellness on a global scale."
Simon has spoken at previous Benzinga cannabis events sharing valuable tips for businesses within the burgeoning industry. The upcoming two-day event, the 19th Benzinga Cannabis Capital Conference, returns to Chicago this Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices surge by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/01101339/ccc-oct-24-banner__1_-2.gif" alt="" class="wp-image-574784" /></a></figure>
<a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic</a>, senior analyst at Zuanic &amp; Associates <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40036301/tilray-should-be-a-long-term-holding-in-any-global-portfolio-of-cannabis-stocks-say">wrote in his post-earnings</a> analyst note that "TLRY should be a long-term holding in any global portfolio of cannabis stocks,&#8221; adding the company&#8217;s liquidity, large market cap and notable cash balance, plus assets, make it a &#8220;more credible&#8221; long-term investment.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/07/40076821/tilray-ceo-on-future-of-cannabis-and-federal-rescheduling-we-did-not-sit-back-and-wait">Tilray CEO On Future Of Cannabis And Federal Rescheduling: &#8216;We Did Not Sit Back And Wait&#8217;</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Recent Moves</h3>
In early September, Tilray <a href="https://www.benzinga.com/markets/cannabis/24/09/40690381/billion-dollar-cannabis-company-closes-acquisition-of-three-us-breweries-whats-next-for-tilray">closed on acquisitions</a> of four U.S. breweries from from Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>). The acquisitions of Hop Valley Brewing Company,Terrapin Beer Co., Revolver Brewing and <a href="https://www.benzinga.com/markets/cannabis/24/09/40852419/billion-dollar-marijuana-giant-buys-another-brewery-from-molson-coors-expands-great-lakes-footpr">Atwater Brewery</a>, bolstered the company's leadership position in the U.S. craft beer market as the 5th largest craft brewer in the country and top craft brewer in the Pacific Northwest and Georgia.
Meanwhile, Tilray did not neglect the cannabis side of its business.
In August, the company <a href="https://www.benzinga.com/markets/cannabis/24/08/40510926/tilray-is-not-giving-up-on-cannabis-ramps-up-its-canadian-portfolio-on-heels-of-buying-four-us-b">announced the release</a> of its latest small-batch flower strain, Milk &amp; Cookies, under its premium cannabis brand Broken Coast.
In addition to the launch of Redecan EU-GMP-certified medical <a href="https://www.benzinga.com/topic/australia">marijuana products in Australia,</a> Tilray also introduced a new line of hemp-derived Delta-9 THC <a href="https://www.benzinga.com/markets/cannabis/24/09/41009554/tilray-brands-launches-hemp-derived-delta-9-thc-drinks-in-key-u-s-markets">beverages across key U.S. markets in September</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40901036/tilray-acquires-23-8m-promissory-note-in-deal-with-double-diamond-on-heels-of-brewery-acquisitio">&nbsp;Tilray Acquires $23.8M Promissory Note In Deal With Double Diamond On Heels Of Brewery Acquisition</a></li>
</ul>
<h3 class="wp-block-heading">TLRY Price Action</h3>
Tilray's shares traded 0.8523% lower at $1.745 per share at the time of writing on Tuesday morning.

Billion-Dollar Cannabis Giant Tilray To Report Earnings, Here's What Investors Can Expect

AKAN

CRON

IMCC

LFLY

MAPS

MSOS

Lawmakers Urge DEA To Finalize Marijuana Rescheduling Proposal

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) stock is trading higher on Monday, along with other shares in the cannabis sector, following a report suggesting that Vice President Kamala Harris wants to <a href="https://www.benzinga.com/markets/cannabis/24/09/41009554/tilray-brands-launches-hemp-derived-delta-9-thc-drinks-in-key-u-s-markets">legalize marijuana</a>.
What To Know: Harris said in an <a href="https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-as-democratic-presidential-nominee/">interview</a> on the All the Smoke podcast that, &#8220;I just think we have come to a point where we have to understand that we need to legalize it and stop criminalizing this behavior.&#8221;
Harris also stated that, &#8220;I just feel strongly, people should not be going to jail for smoking weed. And we know historically what that has meant and who has gone to jail."
The episode of the podcast was released Monday. Its hosts are former NBA players Matt Barnes and Stephen Jackson. Other stocks in the cannabis sector that are moving higher following Harris&#8217;s comments, include Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) and Canopy Growth Corporation (NASADQ:CGC)
How To Buy Tilray Brands Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/markets/cannabis/24/09/41096880/gop-senator-leads-bipartisan-effort-to-seal-low-level-marijuana-possession-records-providing-sec">GOP Senator Leads Bipartisan Effort To Seal Low-Level Marijuana Possession Records, Providing &#8216;Second Chance&#8217;</a>
TLRY Price Action: At the time of writing, Tilray shares are trading 2.59% higher at $1.78, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo by noexcusesradio via Pixabay

What's Going On With Tilray Brands Stock Monday?

WIIM

Shares of cannabis stocks are trading higher following a report suggesting that Vice President Harris wants to legalize marijuana.

<a href="https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-as-democratic-presidential-nominee/">https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-as-democratic-presidential-nominee/</a>
Vice President Kamala Harris says it's time to legalize marijuana—marking the first time she has publicly discussed her position on cannabis since becoming the Democratic presidential nominee.
"I just feel strongly, people should not be going to jail for smoking weed," she said in an interview with the All the Smoke podcast that was released on Monday. "And we know historically what that has meant and who has gone to jail."
"Second, I just think we have come to a point where we have to understand that we need to legalize it and stop criminalizing this behavior," Harris told hosts Matt Barnes and Stephen Jackson, who are former NBA players.
"Actually this is not a new position for me," Harris, who sponsored a federal cannabis legalization bill as a U.S. senator, said. "I have felt for a long time we need to legalize it. So that's where I am on that."
Until now, Harris had not made her position on marijuana part of her current campaign for the White House.
Earlier this month, <a href="https://www.marijuanamoment.net/marijuana-legalization-is-an-issue-for-the-states-vp-candidate-tim-walz-says-adding-that-electing-democrats-to-congress-will-boost-cannabis-reform/">Democratic vice presidential nominee Tim Walz said he thinks marijuana legalization is an issue that should be left to individual states</a>, adding that electing more Democrats to Congress could also make it easier to pass federal reforms like cannabis banking protections.
"I think it's an issue for the states on some of those, and that's the way the states have done it," Walz, who is Minnesota's governor and previously served in Congress, said, dodging a reporter's direct question about national cannabis legalization.
During that interview, Walz highlighted two incremental reform issues: medical marijuana access for veterans who receive healthcare through the Department of Veterans Affairs (VA) as well as passage of federal legislation that would ease restrictions for banks that due business with marijuana companies.
If Democrats take control of both houses of Congress, he said, those matters might be easier to address.
"There's work to be done nationally around the banking issue," he said in the Spectrum News&nbsp;interview&nbsp;that was posted on September 14, "and I think that's something that if we get a working Congress who actually wants to solve some issues—when we have the Democrats in charge of the House and the Senate—then we can start to see if some of those things make sense."
Harris, for her part, has spoken in favor of federal legalization in the past, for example at&nbsp;<a href="https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-since-joining-biden-ticket-signaling-potential-shift-ahead-of-election/">a closed-door roundtable event with cannabis pardon recipients</a> in March. In her previous run for president, Harris also&nbsp;<a href="https://www.marijuanamoment.net/harris-backed-broad-drug-decriminalization-during-2020-election-run-resurfaced-aclu-questionnaire-shows/">backed full federal decriminalization for simple drug possession</a>.
Meanwhile former President Donald Trump said recently during his campaign for a second term that he now supports federal marijuana rescheduling and marijuana banking access.
"As President, we will continue to focus on research to unlock the medical uses of marijuana to a Schedule 3 drug, and work with Congress to pass common sense laws, including safe banking for state authorized companies, and supporting states rights to pass marijuana laws, like in Florida, that work so well for their citizens," Trump posted to social media earlier this month.
<a href="https://www.marijuanamoment.net/trump-says-florida-marijuana-legalization-ballot-measure-will-be-very-good-for-the-state-adding-that-medical-use-is-absolutely-amazing-for-patients/">Trump also recently discussed the medical benefits</a>&nbsp;of cannabis and said legalization would be "very good" for Florida, which will consider the reform at the ballot box in November's election.
The Harris–Walz campaign, however, has&nbsp;<a href="https://www.marijuanamoment.net/harris-campaign-accuses-trump-of-lying-about-marijuana-reform-support-but-again-declines-to-detail-her-own-platform/">accused Trump of lying about his support for marijuana reform</a>—arguing that his "blatant pandering" runs counter to his administration's record on cannabis.
Following Trump's recent announcement of support for the Florida cannabis legalization ballot measure, the Democratic campaign has been working to remind voters that while in office, <a href="https://www.marijuanamoment.net/harris-accuses-trump-of-brazen-flip-flops-on-marijuana-as-former-president-endorses-florida-legalization-measure/">Trump "took marijuana reform backwards."</a>
In a memo from a senior campaign spokesperson, the Harris-Walz campaign accused Trump of "brazen flip flops" on cannabis, saying it's one of the Republican former president's "several bewildering ‘policy proposals' that deserve real scrutiny."
The posturing by the presidential candidates comes amid an ongoing process of moving marijuana to the less-restrictive Schedule III of the Controlled Substances Act (CSA).
The Department of Health and Humans Services (HHS) this spring recommended moving the drug to Schedule III, but the action has faced resistance from the Drug Enforcement Administration (DEA), which has&nbsp;<a href="https://www.marijuanamoment.net/dea-schedules-hearing-on-marijuana-rescheduling-proposal-delaying-final-rule/">scheduled a hearing on the proposal for December 2</a>—after the presidential election,&nbsp;<a href="https://www.marijuanamoment.net/dea-pushing-marijuana-rescheduling-past-election-is-incredibly-disappointing-congressman-says-as-stakeholders-react-to-hearing/">raising concerns that the process will not be completed</a>&nbsp;until after a new president is inaugurated.
Meanwhile, Trump also recently&nbsp;<a href="https://www.marijuanamoment.net/trump-claims-harris-jailed-thousands-and-thousands-of-black-people-over-marijuana-but-her-actual-record-as-a-prosecutor-is-more-nuanced/">went after Harris over her prosecutorial record on marijuana</a>, claiming that she put "thousands and thousands of Black people in jail" for cannabis offenses—but the full record of her time in office is more nuanced.
Trump's line of attack, while misleading, was nonetheless notable in the sense that the GOP presidential nominee implied that he disagrees with criminalizing people over marijuana and is moving to leverage the idea that Harris played a role in racially disproportionate mass incarceration.
As president, Trump largely stayed true to his position that marijuana laws should be handled at the state-level, with no major crackdown on cannabis programs as some feared after then-Attorney General Jeff Sessions rescinded the Obama era federal enforcement guidance. In fact, Trump&nbsp;<a href="https://www.marijuanamoment.net/gop-senator-reveals-what-trump-said-about-jeff-sessionss-anti-marijuana-moves/">criticized the top DOJ official and suggested the move should be reversed</a>.
While he was largely silent on the issue of legalization, he did tentatively endorse a bipartisan bill to&nbsp;<a href="https://www.marijuanamoment.net/trump-says-he-supports-senate-marijuana-legislation/">codify federal policy respecting states' rights to legalize</a>.
That said, on several occasions he released signing statements on spending legislation stipulating that he&nbsp;<a href="https://www.marijuanamoment.net/trump-issues-signing-statement-on-medical-marijuana-provision-of-funding-bill/">reserved the right to ignore a long-standing rider</a>&nbsp;that prohibits the Justice Department from&nbsp;<a href="https://www.marijuanamoment.net/trump-says-he-can-ignore-medical-marijuana-protections-passed-by-congress/">using its funds to interfere with state-legal medical marijuana programs</a>.
Before President Joe Biden bowed out of the race, his campaign made much of the president's mass cannabis pardons and rescheduling push,&nbsp;<a href="https://www.marijuanamoment.net/biden-smokes-trump-on-marijuana-policy-campaign-says-after-presidents-rescheduling-announcement/">drawing a contrast with the Trump administration's record</a>. The Harris campaign so far has not spoken to that particular issue, and the nominee has yet to publicly discuss marijuana policy issues since her own campaign launched.

Macro Economic Events

Politics

Econ #s

General

"Kamala Harris Says 'We Need To Legalize' Marijuana For First Time As Democratic Presidential Nominee" - Marijuana Moment

<a href="https://cannabiswire.com/news/2024/09/26/for-the-first-time-national-agriculture-regulators-group-grapples-with-cannabinoid-hemp/">https://cannabiswire.com/news/2024/09/26/for-the-first-time-national-agriculture-regulators-group-grapples-with-cannabinoid-hemp/</a>
&nbsp;

"National Agriculture Regulators Group Grapples With Intoxicating Hemp For The First Time; FDA's Norm Birenbaum Says Existing FDA Regulatory Frameworks 'Do Not Apply To Large Segments Of The Market, Like Inhalable Products, Where We Have Tremendous Concerns'" - Cannabis Wire

Canadian <a href="http://benzinga.com/cannabis">cannabis</a> powerhouse Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), announced Tuesday that it has launched a new line of hemp-derived Delta-9 THC beverages across key U.S. markets. 
The drinks, set to debut in October, include a range of mocktails, seltzers and sparkling beverages crafted with premium hemp extracts. This move marks Tilray's strategic expansion into the fast-growing <a href="https://www.benzinga.com/topic/cannabis-beverages">hemp-derived THC beverage</a> category.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Tilray Targets Growing Cannabis Beverage Market</h3>
Tilray, already a leader in the cannabis, <a href="http://benzinga.com/topic/hemp">hemp</a> and beverage industries, is leveraging its expertise to meet rising consumer demand for alternative adult beverages. Its new product lineup includes brands like 420 Fizz, Herb &amp; Bloom, Fizzy Jane's and Happy Flower, each with 5mg of Delta-9 THC per can. These products will target a variety of occasions and consumer price points, appealing to diverse audiences.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40509701/hemp-derived-thc-beverages-navigating-regulatory-uncertainty-in-a-potential-13-5b-market">Hemp-Derived THC Beverages: Navigating Regulatory Uncertainty In A Potential $13.5B Market</a>
<h3 class="wp-block-heading">Eyeing Broader Expansion In U.S.</h3>
Tilray's push into the Delta-9 THC space builds on its established presence in the hemp food and craft beer markets. As consumers explore <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40326384/budget-friendly-high-thc-beverages-the-untapped-niche-investors-cant-afford-to-miss">new adult beverage options</a>, the company aims to capture market share by offering a premium, responsibly formulated product experience.&nbsp;
The initial portfolio will roll out in states like <a href="http://benzinga.com/topic/texas-cannabis">Texas</a> and <a href="http://benzinga.com/topic/louisiana-cannabis">Louisiana</a>, with plans for future expansion.
TLRY Price Action TLRY's shares were trading 4.44% higher at $1.76 per share at the time of this writing around noon ET Tuesday.
Related News
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40956859/hemp-derived-products-like-delta-8-thc-are-here-to-stay-says-analyst">Hemp-Derived Products Like Delta-8 THC Are &#8216;Here To Stay,&#8217; Says Analyst</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40945349/cannabis-companies-have-missouris-governor-beat-hemp-thc-products-sales-resume-as-stricter-contr">Cannabis Companies Have Missouri&#8217;s Governor Beat: Hemp-THC Products Sales Resume As Stricter Controls Replace Sweeping Ban</a></li>
</ul>
Image courtesy of Tilray.

Tilray Brands Launches Hemp-Derived Delta-9 THC Drinks In Key U.S. Markets

<a href="https://www.marijuanamoment.net/dea-calls-for-massive-increases-in-psilocybin-ibogaine-and-thc-manufacturing-this-year-to-meet-research-demands/">https://www.marijuanamoment.net/dea-calls-for-massive-increases-in-psilocybin-ibogaine-and-thc-manufacturing-this-year-to-meet-research-demands/</a>
The Drug Enforcement Administration (DEA) is proposing a dramatic increase in its 2023 production quotas for marijuana compounds and psychedelics like psilocybin and ibogaine to "support research and clinical trials" into the substances.
DEA wants to nearly double the amount of psilocybin, psilocyn and delta-9 THC that's manufactured compared to initial levels set for this year, while quintupling how much ibogaine is produced. It also wants 23 times as much of "other tetrahydrocannabinol," raising the quota from 15,000 grams to 350,000 grams for 2023.
The agency had already increased its initial quota for various controlled substances, including cannabis and psychedelics, late last year when it finalized the numbers. But now, in a notice published in the Federal Register on Tuesday, DEA said that more significant changes are warranted.
For psilocybin, the proposed new quota is 15,000 grams, rather than 8,000 grams as previously set for 2023. DEA also wants 24,000 grams of the psychedelic compound psilocyn, double its prior 12,000-gram quota.
The now-increased initial 2023 levels for both of the "magic mushroom" components already represented significant increases from those set for prior years, demonstrating the ongoing heightened level of interest in researching psychedelics over time.
DEA is also proposing to manufacture 150 grams of ibogaine—five times the amount it called for in December 2022.
While the agency didn't change its 6.7 million-gram quota for marijuana for the year, it is now calling for the manufacturing of 628,460 grams of delta-9 THC, rather than 384,460 grams—a 63 percent increase.
For all other tetrahydrocannabinol, DEA wants 350,000 grams, a notable increase from its prior 15,000-gram quota—a massive 2,233 percent increase.
The proposed increases, which are subject to a 30-day public comment period starting on Tuesday, comes in the context of an ongoing administrative review into the scheduling status of cannabis that DEA is actively carrying after receiving a recommendation from the U.S. Department of Health and Human Services (HHS) to <a href="https://www.marijuanamoment.net/top-federal-health-agency-releases-highly-redacted-marijuana-scheduling-recommendation-letter-to-dea/">move marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA)</a>.
It also comes as experts await a <a href="https://www.marijuanamoment.net/after-latest-clinical-trial-mdma-therapy-for-ptsd-is-on-track-for-fda-consideration-next-year/">potential federal approval for certain psychedelics like psilocybin and MDMA</a> as therapeutics for the treatment of serious mental health conditions.
The updated quotas reflect "the estimated medical, scientific, research, and industrial needs of the U.S., for lawful export requirements, and for the establishment and maintenance of reserve stocks," DEA <a href="https://www.federalregister.gov/public-inspection/2023-23931/proposed-adjustments-to-the-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances">said</a> in its new quota increase notice.
"DEA is proposing increases to the [aggregate production quotas] for the following schedule I substances: all other tetrahydrocannabinol, delta-9-tetrahydrocannabinol, ibogaine, psilocybin, and psilocyn," it said. "These proposed increases are to support research and clinical trials by DEA-registered schedule I researchers. These proposed increases demonstrate DEA's support for research with schedule I controlled substances."
 DEA's prior "final" quotas that were published late last year already <a href="https://www.marijuanamoment.net/dea-proposes-dramatic-increases-in-marijuana-and-psychedelics-production-in-2023-for-research/">contained increases compared to its initial proposal</a>, with <a href="https://www.marijuanamoment.net/dea-proposes-even-higher-2023-production-quotas-for-psychedelics-like-mdma-and-psilocyn/">the agency calling for the manufacturing of more psychedelic compounds</a> such as MDMA, psilocyn and 5-MeO-DMT.
This year's 6.7 million-gram quota for marijuana is more than double DEA's final <a href="https://www.marijuanamoment.net/dea-again-boosts-2022-production-goals-for-psychedelics-like-psilocybin-mdma-and-dmt/">cannabis quota for 2022, which was 3.2 million grams.</a>&nbsp;<a href="https://www.marijuanamoment.net/dea-boosts-psilocybin-mdma-and-dmt-production-levels-again-in-final-quotas-for-2021/">It was 2 million grams for 2021</a>.
Growing millions of grams of cannabis may be easier since&nbsp;<a href="https://www.marijuanamoment.net/dea-finally-breaks-federal-marijuana-grower-monopoly-with-two-new-companies-harvesting-cannabis-approved-by-agency/">DEA finally authorized additional manufacturers</a>&nbsp;at the beginning of the year. Those approved cultivators are now able to apply for&nbsp;<a href="https://www.marijuanamoment.net/top-federal-drug-agency-seeking-marijuana-grower-able-to-cultivate-and-analyze-4-million-grams-of-cannabis/">a contract to be federal marijuana suppliers</a>&nbsp;for study purposes under the National Institute on Drug Abuse (NIDA).
The agency has touted its Schedule I drug production quotas as evidence that is supports rigorous research into the substances, but it's faced criticism from advocates and scientists over actions that are viewed as antithetical to promoting studies.
Following pushback, DEA recently retreated on&nbsp;<a href="https://www.marijuanamoment.net/dea-abandons-proposal-to-ban-two-more-psychedelics-after-being-challenged-by-scientists/">a proposed ban on psychedelic compounds</a>&nbsp;that scientists say have research value.
That marked another win for scientific community, coming just one month after DEA&nbsp;<a href="https://www.marijuanamoment.net/dea-cancels-proposed-ban-of-five-psychedelics-giving-scientists-more-time-to-research-therapeutic-benefits/">abandoned separate plans to place five tryptamine psychedelics in Schedule I</a>.
Meanwhile, a federal appeals court recently ruled against DEA in a <a href="https://www.marijuanamoment.net/federal-appeals-court-rules-against-dea-in-psilocybin-rescheduling-lawsuit-brought-by-doctor-who-wants-to-give-psychedelic-to-cancer-patients/">lawsuit over a Washington State doctor's petition to reschedule psilocybin</a>. The court said DEA failed to explain its reasoning when it denied the petition, and it ordered the agency to provide a more complete justification.
With respect to the agency's marijuana scheduling review, a coalition of 31 bipartisan House lawmakers has sent a letter to DEA Administrator Anne Milgram, urging her to <a href="https://www.marijuanamoment.net/31-bipartisan-house-lawmakers-push-dea-to-consider-merits-of-marijuana-legalization-as-it-completes-scheduling-review/">take into account congressional and state marijuana legalization efforts</a> as it completes that assessment. They also criticized the limitations of simple rescheduling as they push for complete a complete removal of marijuana from the CSA.
The letter serves as a counterbalance to other recent messages DEA has received from congressional opponents of reform and former DEA and White House drug czars who&nbsp;<a href="https://www.marijuanamoment.net/marijuana-rescheduling-would-supersize-the-industry-former-dea-heads-and-white-house-drug-czars-warn-biden-administration/">argue that even moving marijuana to Schedule III would go too far</a>.
A coalition of 14 Republican congressional lawmakers recently&nbsp;<a href="https://www.marijuanamoment.net/14-gop-congressional-lawmakers-tell-dea-to-keep-marijuana-in-schedule-i-and-reject-top-health-agencys-recommendation/">urged DEA to "reject" the top federal health agency's recommendation to reschedule marijuana</a>&nbsp;and instead keep it in the most restrictive category under the CSA.
Meanwhile, two GOP senators, including the lead Republican sponsor of&nbsp;<a href="https://www.marijuanamoment.net/watch-live-a-u-s-senate-committee-is-voting-on-a-marijuana-banking-bill/">a marijuana banking bill that cleared a key committee last month</a>, recently filed new legislation to&nbsp;<a href="https://www.marijuanamoment.net/gop-senators-file-bill-to-block-biden-marijuana-rescheduling-effort-without-congressional-approval/">prevent federal agencies from rescheduling cannabis&nbsp;without tacit approval from Congress</a>.

Biotech

CMPS

CYBN

DRUG

ENVB

MNMD

SEEL

'DEA Calls For Massive Increases In Psilocybin, Ibogaine And THC Manufacturing This Year To Meet Research Demands'  - Marijuana Moment

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 1491.67% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 42.26% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 22.73% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 18.97% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 16.58% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 11.52% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 4.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 3.95% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/OGI">OrganiGram Holdings</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed up 3.26% at $1.80</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 3.05% at $0.17</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 61.70% at $19.51</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 31.03% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 18.03% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 13.85% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 10.27% at $2.95</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 10.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 9.18% at $0.85</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 7.76% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 5.76% at $1.31</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed down 5.50% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 5.12% at $2.04</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed down 4.94% at $0.51</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 4.76% at $1.99</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 4.59% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 3.53% at $10.67</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.38% at $1.72</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 3.33% at $0.47</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 3.15% at $0.26</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 3.02% at $11.04</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLGVF

BMMJ

CNTMF

CPHRF

EAST

FUAPF

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

MRMD

NWVCF

OILFF

RMHB

TCNNF

Cannabis Stock Movers For September 20, 2024

Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>) announced on Wednesday the launch of Redecan EU-GMP certified medical <a href="https://www.benzinga.com/topic/australia">cannabis products in Australia</a>.
What Happened: The following&nbsp;Redecan&nbsp;products are now available for medical cannabis patients in&nbsp;Australia, including:
<ul>
<li>Redecan PC THC28 Purple Churro – 15g</li>
<li>Redecan SA THC28 Space Age Cake – 15g</li>
</ul>
Why It Matters: Denise Faltischek, chief strategy officer and head of international at Tilray Brands, praised the move.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/22/08/28597648/tilrays-cbd100-approved-for-clinical-trials-in-australia-and-new-zealand-by-the-natural-health-s">Tilray&#8217;s CBD100 Approved For Clinical Trials In Australia And New Zealand By The Natural Health Science Foundation</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
"The launch of Redecan further expands our medical cannabis portfolios alongside our current Tilray and Broken Coast offerings, as we continue our mission of empowering patients and healthcare practitioners to find the optimal therapeutic solutions," Faltischek said.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18084431/ccc-oct-24-banner__1_-26.gif" alt="" class="wp-image-553913" /></a></figure>
Jonathan Trodden, director at Tilray Medical Australia, agrees: "We are proud to launch Redecan in Australia and further strengthen our ongoing commitment to providing patients with a consistent, accessible supply of premium quality medical cannabis to choose from.&#8221;
Tilray has been present in Australia for years. In 2022, the company launched a new medical cannabis e-learning platform for healthcare providers, built on the importance of understanding the benefits derived <a href="https://www.benzinga.com/markets/cannabis/22/01/25204825/tilray-expands-medical-marijuana-product-offering-in-australia-launches-cannabis-e-learning-plat">from medical cannabis use</a>. This effort followed Tilray&#8217;s successful introduction of multiple medical cannabis workshops across Australia and New Zealand, educating hundreds of healthcare practitioners in 2021.
Price Action: Tilray's shares traded 0.51% higher at $1.8193 per share during the pre-market session on Wednesday morning.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/03/37706111/weed-giants-tilray-and-curaleaf-ramp-up-presence-in-europe-heres-why">Weed Giants Tilray And Curaleaf Ramp Up Presence In Europe, Here&#8217;s Why</a></li>
</ul>

Cannabis Giant Tilray Expands Medical Marijuana Portfolio With Redecan Launch In Australia

Tilray Q1 2025 Earnings Preview

Village Farms Offers Cannabis Investors A Fantastic Opportunity

Here's the major earnings before the open tomorrow

Tilray Non-GAAP EPS of -$0.01 beats by $0.02, revenue of $200.04M misses by $20.8M

Today, several major companies are expected to report earnings: Aehr Test Systems (AEHR), Delta Air Lines (DAL), Domino's Pizza (DPZ), Neogen (NEOG...

Options Volatility and Implied Earnings Moves Today, October 10, 2024

Earnings Snapshot: Tilray Brands reports mixed FQ1 with 13% growth in revenue and 38% reduction in net loss

Tilray sees better days for cannabis amid U.S. presidential race

Tilray Brands in charts: Cannabis business struggles in FQ1 '25

Tilray (TLRY) has released an update. Tilray Brands, Inc., a player in the burgeoning cannabis industry, has filed a current report on Form 8-K wit...

Tilray Brands Files Regulatory 8-K Form with SEC

Shares of Tilray Brands ($TLRY) plummeted in trading on Thursday after the cannabis-lifestyle and consumer packaged goods company's Fiscal Q1 reven...

TLRY Earnings: Tilray Brands Plummets as Q1 Revenues Fall Short of Estimates

AEHR

NEOG

Press Releases

Breckenridge Brewery Unveils Oktoberfest Brew and Hosts 28th Annual Oktoberfest Festival: A Weekend of Live Music, Traditional German Cuisine, and Tasty Brews in Breckenridge, Colorado

Tilray Brands Completes Acquisition of Atwater Brewery From Molson Coors Beverage Company

Tilray Medical Launches Redecan Cannabis Brand in Australia

Sports

Shock Top Announces its Official Craft Beer Sponsorship of University of Missouri Athletics

Restaurants

Tilray Brands Leverages Hemp and Beverage Scale to Launch Hemp-Derived Delta-9 THC Drinks in Key Markets Across the United States

Shock Top's Bold New Hard Iced LiiT Tea is Here

Tilray Brands, Inc. to Announce First Quarter Fiscal Year 2025 Financial Results on October 10, 2024

Comments

Tilray Brands

Interés en corto

Tilray Brands (NASDAQ:TLRY) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL